Stage III NSCLC RWE in Chinese Patients
Real-World Molecular Testing, Treatment Patterns and Clinical Outcomes in Chinese Patients With Stage III NSCLC- A Prospective, Non-Interventional Study(MOOREA)
1 other identifier
observational
500
1 country
25
Brief Summary
The objectives of this study are to assess molecular testing, treatment patterns and associated clinical outcomes in Chinese patients with treatment-naïve stage III non-small cell lung cancer (NSCLC) in real world setting. This study is a prospective, non-interventional study. It is descriptive in nature and does not attempt to test any specific a priori hypotheses.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2019
Longer than P75 for all trials
25 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 30, 2019
CompletedStudy Start
First participant enrolled
July 16, 2019
CompletedFirst Posted
Study publicly available on registry
July 18, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 29, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
February 29, 2024
CompletedFebruary 18, 2025
February 1, 2025
4.6 years
May 30, 2019
February 14, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To observe treatment patterns of unresectable, stage III NSCLC
Treatment received before disease progress including chemotherapy, targeted therapy, immunotherapy, anti-angiogenesis therapy and radiotherapy
Date of enrollment in the study until end of follow-up or death if this occurs before, assessed approximately up to 36 months
Secondary Outcomes (4)
To observe the clinical outcome of unresectable, stage III NSCLC
Date of enrollment in the study until end of follow-up or death if this occurs before, assessed approximately up to 36 months
To observe molecular testing patterns of stage III NSCLC
Date of enrollment in the study until end of follow-up or death if this occurs before, assessed approximately up to 36 months
To estimate parameters associated with radiation pneumonitis
Date of enrollment in the study until end of follow-up or death if this occurs before, assessed approximately up to 36 months
To observe adjuvant treatment patterns of resectable, stage III NSCLC
Date of enrollment in the study until end of follow-up or death if this occurs before, assessed approximately up to 36 months
Study Arms (2)
Cohort 1
Cohort 1, including patients without surgical resection, will be defined as unresectable stage III NSCLC
Cohort 2
Cohort 2,including patients with surgical resection, will be defined as resectable stage III NSCLC
Eligibility Criteria
Stage III NSCLC patients who received no prior systemic therapy for NSCLC before study enrolment
You may qualify if:
- Male or female aged 18 years or older.
- Provision of informed consent prior to any study specific procedures.
- Histologically or cytologically confirmed locally advanced, stage III NSCLC (according to version 8 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology; IASLC Staging Manual in Thoracic Oncology).
You may not qualify if:
- Enrolment in studies that prohibit any participation in this observational study.
- Patients may be concurrently enrolled in unblinded clinical trials, but not blinded clinical trials in which the treatment being administered is unknown.
- Prior surgery, radiotherapy or systemic therapy for NSCLC, including chemotherapy, targeted therapy, anti-angiogenesis, etc.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (25)
Research Site
Beijing, China, 100020, China
Research Site
Beijing, China, 100044, China
Research Site
Beijing, China, China
Research Site
Datong, China, 030000, China
Research Site
Datong, China, China
Research Site
Fenyang, China, China
Research Site
Guangzhou, China, China
Research Site
Hefei, China, 330006, China
Research Site
Jinan, China, 2501117, China
Research Site
Nanning, China, 530021, China
Research Site
Qingdao, China, China
Research Site
Shantou, China, China
Research Site
Taizhou, China, China
Research Site
Tianjin, China, China
Research Site
Yinchuan, China, 750004, China
Research Site
Changchun, 130021, China
Research Site
Chengdu, 610041, China
Research Site
Chengdu, 610042, China
Research Site
Hong Kong, China
Research Site
Shanghai, 200030, China
Research Site
Shanghai, 200040, China
Research Site
Shanghai, China
Research Site
Shijiazhuang, 050011, China
Research Site
Shijiazhuang, 063000, China
Research Site
Shijiazhuang, 430079, China
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 30, 2019
First Posted
July 18, 2019
Study Start
July 16, 2019
Primary Completion
February 29, 2024
Study Completion
February 29, 2024
Last Updated
February 18, 2025
Record last verified: 2025-02